Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. .

Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector

Akcea Announces Appointment of New Chief Operating Officer

Ionis Pharma

BOSTON and CARLSBAD, Calif., Nov.  25, 2019  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for AKCEA-TTR-LRx in patients with polyneuropathy caused by h856ereditary TTR amyloidosis, or hATTR amyloidosis.

Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

BOSTON and CARSLBAD, Calif., Nov.  19, 2019  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (NYSE:PFE) for AKCEA-ANGPTL3-LRx  following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). 

Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q3 2019 Results - Earnings Call Transcript

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 38.18% and 39.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Akcea Therapeutics (AKCA) Reports Q3 Loss, Tops Revenue Estimates

Alnylam Pharmaceuticals

Eidos Therapeutics Inc

The sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Akcea Therapeutics (AKCA) Upgraded to Strong Buy: Here's Why

Kyle Jenne promoted from previous role as U.S. commercial lead to support continued strategic expansion of global commercial operations Kyle Jenne promoted from previous role as U.S. commercial lead to support continued strategic expansion of global commercial operations

Akcea Announces Appointment of New Chief Commercial Officer

Akcea Therapeutics (AKCA) stock is flying high on Monday following news of a $250 million deal with Pfizer (NYSE:PFE) for licensing rights.
The post Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal appeared first on InvestorPlace.

Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal

A licensing deal gives investors confidence in a turnaround.

Here's Why Akcea Therapeutics Jumped 30% Today

Shares of Akcea Therapeutics rocketed in higher-than-average volume on Monday after the Ionis Pharmaceuticals affiliate announced a licensing deal with Dow Jones component Pfizer.

How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume

Pfizer

Akcea and Ionis to earn $250 million license fee Akcea and Ionis to earn $250 million license fee

Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

Akcea Therapeutics, Inc. (AKCA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Akcea Therapeutics Enters Oversold Territory

Overstock.com

Find out which of these companies investors are the most nervous about.

Why NIO, Akcea Therapeutics, and Overstock.com Slumped Today

Shares of Akcea Therapeutics Inc. AKCA, -10.15% sank 10% in morning trade Monday, after the biopharmaceutical company three of its top executives were leaving the company, including Chief Executive Paula Soteropoulos, effective immediately.

Akcea's stock drops after 3 top executives leave company, including CEO

Damien McDevitt, Ph.D. appointed interim CEO; Michael Yang and Joseph ‘Skip’ Klein join Board of Directors Damien McDevitt, Ph.D. appointed interim CEO; Michael Yang and Joseph ‘Skip’ Klein join Board of Directors

Akcea Announces CEO Transition and Elects Two New Board Members

Data show >90% knockdown of TTR following administration in healthy volunteers

Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

Liver Therapy Forum weekly digest provides an overview on what’s happening in liver diseases in 2019. This week’s spotlight is Akcea Therapeutics.

Akcea Therapeutics And AKCEA-ANGPTL3-LRx I: The Story

AMAG Pharmaceuticals

Ligand Pharmaceuticals

MannKind

Moderna

Paratek Pharma

Viking Therapeutics

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q2 2019 Results - Earnings Call Transcript

Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call Transcript

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -72.58% and -7.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Akcea Therapeutics (AKCA) Q1 Earnings and Revenues Lag Estimates

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Akcea Therapeutics Stock (AKCA)